Kazia Therapeutics (KZIA) FCF Margin (2016)

Kazia Therapeutics (KZIA) posted FCF Margin of 188.56% for Q4 2016.

Kazia Therapeutics (KZIA) FCF Margin (2016) Analysis & Trends

Kazia Therapeutics' FCF Margin history runs 1 years deep, the most recent figure standing at 188.56% for Q4 2016.

Quarterly FCF Margin changed N/A year-over-year to 188.56% in Q4 2016, while the trailing twelve-month figure through Jun 2017 was 39.02% (changed N/A YoY) and the FY2025 annual result came in at 31614.29%, down 3119916.0% from the prior year.
FCF Margin was 188.56% for Q4 2016 at Kazia Therapeutics.
Across five years, FCF Margin topped out at 188.56% in Q4 2016 and bottomed at 188.56% in Q4 2016.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	10.45%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	43.35%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	23.53%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Kazia Therapeutics	4.11 Mn	4.11 Mn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2016	-188.56%